LIF Antibody

Blue Ice

Predicted: 22kD
Observed: 26kD (Post-modifications: N-linked Glycosylations)

LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.

Trial Size

4504991

Human LIF has 2 isoforms, including isoform 1 (202aa, 22kD) and isoform 2 (88aa, 9.6kD). Mouse LIF has 1 isoform (203aa, 22.3kD and Rat LIF also has 1 isoform (202aa, 22.1kD). 6245 can detect human isoform1 as well as mouse and rat LIF.

PRS-1287-0.1mg

1 mg/mL

WB: 1-4 μ g/mL; IF: 20 μ g/mL.
Antibody validated: Western Blot in human, mouse and rat samples; Immunofluorescence in mouse samples. All other applications and species not yet tested.

At least two isoforms of LIF are known to exist.

Polyclonal

Homo sapiens

Optimal dilutions for each application to be determined by the researcher.